Abstract 401P
Background
Academic field in oncology is male dominated in India as it is in the rest of the world. There is a dearth of female oncologists in managerial or leadership posts in oncology. Female oncologists face unique challenges in this field. Female authorship as first or corresponding author is a surrogate marker for the representation of females in the academic world. This study was undertaken to determine the extent of female participation/leadership in oncology in India.
Methods
An online survey was conducted across the women in the field of oncology in India. Also, the issues of Indian Journal of Cancer and Indian Journal of Medical and Paediatric Oncology from January 2017 to December 2018 were examined. The articles with female first or corresponding authors were enumerated.
Results
Of the 153 participants in the survey, 56% were above 40 years of age. 53% of them were clinical oncologists. 65% of the females worked in male majority teams and 67% admitted to working with male managers. Only 31% of the respondents covered a leadership role within their jobs. Family commitments, perception of males as the natural leaders and maintaining a work family balance were quoted to be the most frequent obstacles to career progression. A total of 558 journal publications were inspected. Of these, 145 articles (26%) had a female first author or a corresponding author, of which 94 (64.9%) were original articles. Each issue had a median of 30 publications, of which median of 8 publications (range 3-15) were authored by females. Of the 360 original articles perused, only 94 (26.1%) had female authorship.
Conclusions
This study was undertaken to analyse the participation of females in oncology and allied sciences in India. Only 1/3 of the females were in a leadership position of the 153 survey participants. Majority of the females work in male-dominated work environments and tackle multitude of impediments in advancement in their profession. Objectively, only 26% of the publications in two of the leading oncology journals of India were authored by females. Female first/corresponding authors were found only in 26% of the original articles. More efforts are to be taken for women empowerment and increase the representation of females in this field. More flexible work/training schedules are required for their upliftment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract